Patient characteristics
| Characteristic . | All patients (n = 2656) . |
|---|---|
| Median patient age, y (range) | 39 (0-71) |
| Patient sex, no. (%) | |
| Male | 1528 (58) |
| Female | 1128 (42) |
| Diagnosis at transplantation, no. (%) | |
| Acute myeloid leukemia | 848 (32) |
| Acute lymphoblastic leukemia | 412 (16) |
| Chronic myeloid leukemia | 894 (34) |
| Myelodysplastic syndrome or myeloproliferative neoplasms | 502 (19) |
| Disease risk at transplantation, no. (%)* | |
| Low | 1191 (45) |
| High | 1465 (55) |
| High-intensity conditioning regimens, no. (%) | |
| With total body irradiation | 1628 (61) |
| Without total body irradiation | 1028 (39) |
| HLA and donor type, no. (%) | |
| HLA-identical related | 1088 (41) |
| HLA-matched unrelated | 912 (34) |
| HLA antigen or allele-mismatched related | 243 (9) |
| HLA antigen or allele-mismatched unrelated | 413 (16) |
| Donor/patient sex, no. (%) | |
| Male/male | 873 (33) |
| Female/male | 655 (25) |
| Male/female | 584 (22) |
| Female/female | 544 (20) |
| Graft source, no. (%) | |
| Bone marrow | 1760 (66) |
| Mobilized blood hematopoietic stem cells | 896 (34) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine + methotrexate alone | 1885 (71) |
| Tacrolimus + methotrexate alone | 125 (5) |
| Rabbit antithymocyte globulin + other medications | 74 (3) |
| T cell partially depleted | 15 (1) |
| Other regimens | 557 (21) |
| CMV-positive patient or donor, no. (%) | 1745 (66) |
| Characteristic . | All patients (n = 2656) . |
|---|---|
| Median patient age, y (range) | 39 (0-71) |
| Patient sex, no. (%) | |
| Male | 1528 (58) |
| Female | 1128 (42) |
| Diagnosis at transplantation, no. (%) | |
| Acute myeloid leukemia | 848 (32) |
| Acute lymphoblastic leukemia | 412 (16) |
| Chronic myeloid leukemia | 894 (34) |
| Myelodysplastic syndrome or myeloproliferative neoplasms | 502 (19) |
| Disease risk at transplantation, no. (%)* | |
| Low | 1191 (45) |
| High | 1465 (55) |
| High-intensity conditioning regimens, no. (%) | |
| With total body irradiation | 1628 (61) |
| Without total body irradiation | 1028 (39) |
| HLA and donor type, no. (%) | |
| HLA-identical related | 1088 (41) |
| HLA-matched unrelated | 912 (34) |
| HLA antigen or allele-mismatched related | 243 (9) |
| HLA antigen or allele-mismatched unrelated | 413 (16) |
| Donor/patient sex, no. (%) | |
| Male/male | 873 (33) |
| Female/male | 655 (25) |
| Male/female | 584 (22) |
| Female/female | 544 (20) |
| Graft source, no. (%) | |
| Bone marrow | 1760 (66) |
| Mobilized blood hematopoietic stem cells | 896 (34) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine + methotrexate alone | 1885 (71) |
| Tacrolimus + methotrexate alone | 125 (5) |
| Rabbit antithymocyte globulin + other medications | 74 (3) |
| T cell partially depleted | 15 (1) |
| Other regimens | 557 (21) |
| CMV-positive patient or donor, no. (%) | 1745 (66) |
HLA indicates human leukocyte antigen; GVHD, graft-versus-host disease; and CMV, cytomegalovirus.
The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, and myelodysplastic syndrome without excess blasts. The high-risk category included all other diseases and stages.